Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studiesFENLAITAN; XIAOYAN SHEN; DECHANG WANG et al.Lung cancer. 2012, Vol 76, Num 2, pp 177-182, issn 0169-5002, 6 p.Article

Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy eraJIN HYUN PARK; YU JUNG KIM; LEE, Jeong-Ok et al.Lung cancer. 2012, Vol 76, Num 3, pp 387-392, issn 0169-5002, 6 p.Article

Prediction for response duration to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutated never smoker lung adenocarcinomaHYE RYUN KIM; BYOUNG CHUL CHO; HYO SUP SHIM et al.Lung cancer. 2014, Vol 83, Num 3, pp 374-382, issn 0169-5002, 9 p.Article

Reaction of plasma hepatocyte growth factor levels in non-small cell lung cancer patients treated with EGFR-TKIsTANAKA, Hidenori; KIMURA, Tatsuo; KUDOH, Shinzoh et al.International journal of cancer (Print). 2011, Vol 129, Num 6, pp 1410-1416, issn 0020-7136, 7 p.Article

Continuous Administration of EGFR-TKIs Following Radiotherapy after Disease Progression in Bone Lesions for Non-small Cell Lung CancerINOMATA, Minehiko; SHUKUYA, Takehito; ENDO, Masahiro et al.Anticancer research. 2011, Vol 31, Num 12, pp 4519-4523, issn 0250-7005, 5 p.Article

Survival of lung adenocarcinoma patients with malignant pleural effusionWU, Shang-Gin; YU, Chong-Jen; TSAI, Meng-Feng et al.The European respiratory journal. 2013, Vol 41, Num 6, pp 1409-1418, issn 0903-1936, 10 p.Article

SAA1 is over-expressed in plasma of non small cell lung cancer patients with poor outcome after treatment with epidermal growth factor receptor tyrosine-kinase inhibitorsMILAN, Enrico; LAZZARI, Chiara; ANAND, Santosh et al.Journal of proteomics (Print). 2012, Vol 76, pp 91-101, issn 1874-3919, 11 p.Article

Phase II Study of Erlotinib in Japanese Patients with Advanced Non-small Cell Lung CancerTAKAHASHI, Toshiaki; YAMAMOTO, Nobuyuki; SEGAWA, Yoshihiko et al.Anticancer research. 2010, Vol 30, Num 2, pp 557-563, issn 0250-7005, 7 p.Article

Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinibTARTARONE, Alfredo; LAZZARI, Chiara; LEROSE, Rosa et al.Lung cancer. 2013, Vol 81, Num 3, pp 328-336, issn 0169-5002, 9 p.Article

A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC)XINGSHENG HU; BAOHUI HAN; MEINA WU et al.Lung cancer. 2014, Vol 86, Num 2, pp 207-212, issn 0169-5002, 6 p.Article

Prognostic and Predictive Implications of EGFR Mutations, EGFR Copy Number and KRAS Mutations in Advanced Stage Lung AdenocarcinomaBONANNO, Laura; SCHIAVON, Marco; NARDO, Giorgia et al.Anticancer research. 2010, Vol 30, Num 12, pp 5121-5128, issn 0250-7005, 8 p.Article